Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
摘要:
Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.
Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
摘要:
Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.
Catalytic Asymmetric Cyclopropanation of Allylic Alcohols with Titanium-TADDOLate: Scope of the Cyclopropanation Reaction
作者:André B. Charette、Carmela Molinaro、Christian Brochu
DOI:10.1021/ja0108382
日期:2001.12.1
titanium-TADDOLate complex was effective at catalyzing the cyclopropanation reaction of allylicalcohols in the presence 1 equiv of bis(iodomethyl)zinc. After initial optimization of the catalyst structure, excellent yields and enantiomeric ratios were obtained for 3-aryl- or 3-heteroaryl-substituted allylicalcohols (up to 97:3). Alkyl-substituted allylicalcohols gave modest yields and enantiomeric ratios (up
Highly Enantioselective Intermolecular Cyclopropanation Catalyzed by Dirhodium(II) Tetrakis[3(<i>S</i>)-phthalimido-2-piperidinonate]: Solvent Dependency of the Enantioselection
The enantioselectivity in cyclopropanations catalyzed by dirhodium(II) tetrakis[3(S)-phthalimido-2-piperidinonate] has been found to be substantially improved by employing ether as the rarely used solvent. Cyclopropanations of styrenes or 1,1-disubstituted alkenes with 2,4-dimethyl-3-pentyl diazoacetate in ether are promoted by this catalyst to afford the corresponding cyclopropane products in the highest levels of enantioselectivity (up to 98% ee) reported to date for the dirhodium(II)-catalyzed intermolecular cyclopropanation reactions.
“Box”ed in: A novel polysiloxane gel encapsulated CuII/bis(oxazoline) (CuII/Box) species was synthesized and used as a recyclable catalyst in the asymmetriccyclopropanation of alkenes with L‐menthyl diazoacetate.
在“框” ED:一种新颖的聚硅氧烷凝胶包封的Cu II /双(恶唑啉)(铜II /箱)物种合成并用作与烯烃的不对称环丙烷可回收催化剂大号-薄荷基重氮基。
Enantiomerically pure heteroorganic catalysts, bearing a hydroxy moiety, a stereogenic sulfinyl group, and a chiral aziridine moiety, have proved highly efficient in the asymmetric Simmons–Smithcyclopropanation of allylic alcohols, which generates the desired products in high yields (up to 95 %) and with ee values up to 94 %. The effect of the stereogenic centers at the sulfinyl sulfur atom and in
TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160237081A1
公开(公告)日:2016-08-18
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.